Diabetes News

Endocrinology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

The commercial failure of Exubera, the first inhaled insulin product to come to market, led other companies such as Eli Lilly–Alkermes to halt studies of similar drug delivery in development intended to compete for a share of the lucrative diabetes market. Does this signal defeat for efforts to deliver insulin via the lungs? The science and circumstances behind the Lilly–Alkermes decision to discontinue trials of the AIR inhaled insulin product are explored in a special supplement to Diabetes Technology & Therapeutics.


   

Today in Popular Press...keeping you current

Imaging cuts in Medicare fee schedule: An access catastrophe and danger to patients
EurekAlert, 11/03/09

To eat less, your body may want you to eat slowly
Reuters, 11/10/09

Daily dose of color may boost immunity this flu season
EurekAlert, 11/04/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address